Alejandro Gabriel Schijman
Overview
Explore the profile of Alejandro Gabriel Schijman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
458
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Martinez-Peinado N, Gabaldon-Figueira J, Rodrigues Ferreira R, Carmen Thomas M, Lopez M, Cremonini Araujo-Jorge T, et al.
PLoS Negl Trop Dis
. 2024 Aug;
18(8):e0012166.
PMID: 39146233
Chagas disease, caused by the parasite Trypanosoma cruzi, affects over 6 million people, mainly in Latin America. Two different clinical phases, acute and chronic, are recognised. Currently, 2 anti-parasitic drugs...
2.
Gonzalez Martinez A, Losada-Galvan I, Gabaldon-Figueira J, Martinez-Peinado N, Magalhaes Saraiva R, Fernandez M, et al.
PLoS Negl Trop Dis
. 2024 Aug;
18(8):e0012364.
PMID: 39146231
The NHEPACHA Iberoamerican Network, founded on the initiative of a group of researchers from Latin American countries and Spain, aims to establish a research framework for Chagas disease that encompasses...
3.
Schijman A, Alonso-Padilla J, Britto C, Herrera Bernal C
Lancet Reg Health Am
. 2024 Jul;
36:100821.
PMID: 39006126
Chagas disease, caused by , affects millions worldwide. The 2030 WHO roadmap aims to eliminate it as a public health concern, emphasising the need for timely diagnosis to enhance treatment...
4.
Gabaldon-Figueira J, Skjefte M, Longhi S, Escabia E, Garcia L, Ros-Lucas A, et al.
Expert Rev Anti Infect Ther
. 2023 Nov;
21(12):1287-1299.
PMID: 37933443
Introduction: Chagas disease, caused by parasite , is the most important neglected tropical disease in the Americas. Two drugs are available for treatment, but access to them is challenging, in...
5.
Torrico F, Gascon J, Ortiz L, Pinto J, Rojas G, Palacios A, et al.
Clin Infect Dis
. 2022 Aug;
76(3):e1186-e1194.
PMID: 35925555
Background: Chagas disease (CD) has significant global health impact, but safe, effective treatments remain elusive. The nitroimidazole fexinidazole is a potential treatment. Methods: This double-blind, randomized, placebo-controlled, dose-finding, proof-of-concept study...
6.
Schijman A, Alonso-Padilla J, Longhi S, Picado A
Mem Inst Oswaldo Cruz
. 2022 May;
117:e200444.
PMID: 35613155
There is no consensus on the diagnostic algorithms for many scenarios of Trypanosoma cruzi infection, which hinders the establishment of governmental guidelines in endemic and non-endemic countries. In the acute...
7.
Ramirez J, Acevedo G, Torres C, Parrado R, De La Barra A, Villarroel S, et al.
J Antimicrob Chemother
. 2021 Dec;
77(3):578-584.
PMID: 34865002
Background: The role that the genetic diversity of natural Trypanosoma cruzi populations plays in response to trypanocidal treatment of chronic Chagas disease (CD) patients remains to be understood. We analysed...
8.
Benatar A, Danesi E, Besuschio S, Bortolotti S, Cafferata M, Ramirez J, et al.
EBioMedicine
. 2021 Jun;
69:103450.
PMID: 34186488
Background: Current algorithm for Congenital Chagas Disease (cCD) diagnosis is unsatisfactory due to low sensitivity of the parasitological methods. Moreover, loss to follow-up precludes final serodiagnosis after nine months of...
9.
Kemmerling U, Osuna A, Schijman A, Truyens C
Front Microbiol
. 2019 Sep;
10:1854.
PMID: 31474955
Chagas disease (CD), caused by the protozoan parasite , is considered a neglected tropical disease by the World Health Organization. Congenital transmission of CD is an increasingly relevant public health...
10.
Del-Rei R, Leony L, Celedon P, Zanchin N, Reis M, Gomes Y, et al.
PLoS One
. 2019 Apr;
14(4):e0215623.
PMID: 30998741
Background: Laboratory diagnosis of chronic Chagas disease is a troubling factor due to lack of reference tests. The WHO suggests the use of two distinct commercial serological tests in parallel....